Literature DB >> 12697737

Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.

Tamara Manuelian1, Jens Hellwage, Seppo Meri, Jessica Caprioli, Marina Noris, Stefan Heinen, Mihaly Jozsi, Hartmut P H Neumann, Giuseppe Remuzzi, Peter F Zipfel.   

Abstract

Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Recent studies have identified a factor H-associated form of HUS, caused by gene mutations that cluster in the C-terminal region of the complement regulator factor H. Here we report how three mutations (E1172Stop, R1210C, and R1215G; each of the latter two identified in three independent cases from different, unrelated families) affect protein function. All three mutations cause reduced binding to the central complement component C3b/C3d to heparin, as well as to endothelial cells. These defective features of the mutant factor H proteins explain progression of endothelial cell and microvascular damage in factor H-associated genetic HUS and indicate a protective role of factor H for tissue integrity during thrombus formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697737      PMCID: PMC152934          DOI: 10.1172/JCI16651

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.

Authors:  M R Buddles; R L Donne; A Richards; J Goodship; T H Goodship
Journal:  Am J Hum Genet       Date:  2000-05       Impact factor: 11.025

2.  Each of the three binding sites on complement factor H interacts with a distinct site on C3b.

Authors:  T S Jokiranta; J Hellwage; V Koistinen; P F Zipfel; S Meri
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

Review 3.  Factor H--US?

Authors:  P Warwicker; J A Goodship; T H Goodship
Journal:  Nephrol Dial Transplant       Date:  1998-08       Impact factor: 5.992

4.  The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

Authors:  Jessica Caprioli; Paola Bettinaglio; Peter F Zipfel; Barbara Amadei; Erica Daina; Sara Gamba; Christine Skerka; Nicola Marziliano; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2001-02       Impact factor: 10.121

5.  Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack.

Authors:  N S Fedarko; B Fohr; P G Robey; M F Young; L W Fisher
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

6.  Complement C3b interactions studied with surface plasmon resonance technique.

Authors:  T S Jokiranta; J Westin; U R Nilsson; B Nilsson; J Hellwage; S Löfås; D L Gordon; K N Ekdahl; S Meri
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

Review 7.  Complement factor H and hemolytic uremic syndrome.

Authors:  P F Zipfel; C Skerka; J Caprioli; T Manuelian; H H Neumann; M Noris; G Remuzzi
Journal:  Int Immunopharmacol       Date:  2001-03       Impact factor: 4.932

8.  Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.

Authors:  D Pérez-Caballero; C González-Rubio; M E Gallardo; M Vera; M López-Trascasa; S Rodríguez de Córdoba; P Sánchez-Corral
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

9.  Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.

Authors:  A Richards; M R Buddles; R L Donne; B S Kaplan; E Kirk; M C Venning; C L Tielemans; J A Goodship; T H Goodship
Journal:  Am J Hum Genet       Date:  2001-01-17       Impact factor: 11.025

10.  Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.

Authors:  M Noris; P Ruggenenti; A Perna; S Orisio; J Caprioli; C Skerka; B Vasile; P F Zipfel; G Remuzzi
Journal:  J Am Soc Nephrol       Date:  1999-02       Impact factor: 10.121

View more
  124 in total

1.  Complement system on the attack in autoimmunity.

Authors:  John P Atkinson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 2.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

3.  Complement regulator Factor H mediates a two-step uptake of Streptococcus pneumoniae by human cells.

Authors:  Vaibhav Agarwal; Tauseef M Asmat; Shanshan Luo; Inga Jensch; Peter F Zipfel; Sven Hammerschmidt
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

6.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: emerging insights for vascular integrity.

Authors:  Peter Densen
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

7.  The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein.

Authors:  M Oppermann; T Manuelian; M Józsi; E Brandt; T S Jokiranta; S Heinen; S Meri; C Skerka; O Götze; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

8.  Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement.

Authors:  Tommi Kajander; Markus J Lehtinen; Satu Hyvärinen; Arnab Bhattacharjee; Elisa Leung; David E Isenman; Seppo Meri; Adrian Goldman; T Sakari Jokiranta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-01       Impact factor: 11.205

9.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

10.  Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population.

Authors:  R Martínez-Barricarte; E Goicoechea de Jorge; T Montes; A G Layana; S Rodríguez de Córdoba
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.